Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.


  1. Advanced Patent Search
Publication numberUS3274063 A
Publication typeGrant
Publication dateSep 20, 1966
Filing dateJun 21, 1961
Priority dateJul 24, 1958
Also published asDE1099128B, DE1131847B
Publication numberUS 3274063 A, US 3274063A, US-A-3274063, US3274063 A, US3274063A
InventorsNieper Hans Alfred, Escherich Georg
Original AssigneeMarbert Kosmetik Fa
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Cosmetic cream
US 3274063 A
Abstract  available in
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

United States Patent Ofi COSMETIC CREAM Hans Alfred Nieper, Aschaffenburg, and Georg Escherich, Melsungen, Hesse, Germany, assignors to Firma Marbert-Kosmetik, Roeber and Sendler, Dusseldorf, Germany No Drawing. Filed June 21, 1961, Ser. No. 118,495 Claims priority, application Germany, July 24, 1958,

N 15,392; Sept. 22, 1958, N 15,614 4 Claims. (Cl. 167-91) The invention relates to cosmetic preparations, particularly to cosmetic creams, and is a continuation-inpart of our application Ser. No. 828,721, filed July 22, 1959, now abandoned.

Cosmetic creams usually comprise emulsion systems of the oil-in-water, or water-in-oil type, or combinations thereof. They are used, for instance, as cold creams or vanishing creams, for smoothing and softening the skin.

We have found that if a small amount of magnesium aspartate (also known as magnesium asparaginate) is added to a cosmetic cream, the properties of the cream are considerably improved as far as the effect on the skin is concerned. Already after short use, the skin becomes much softer and smoother than when ordinary cosmetic creams are used.

Accordingly, a cosmetic cream in accordance with the invention includes about 0.05 to 10 percent by weight of magnesium aspartate.

We believe that the considerable improvement in the properties of a cosmetic cream containing magnesium aspartate is due to the facts that on the one hand, magnesium in form of said salt is only slightly dissociated in the blood and body liquids, passes easily through the cell walls, and then readily exerts its particular effects inside the cell.

The effect of intracellular magnesium consists in an activation of the metabolism ferments of thee esterase type. Such activation improves the growth of the basal layer of the epidermis and produces an increased bonding of intracellular water, increasing the size and tension of the cells.

It appears that the easy migration of the magnesium aspartate through the cell walls is due to the affinity of the aspartic acid to the cells of the epithelial tissue and to the relatively high complex constant of the salt.

The magnesium salt of glutamic acid, which, like aspartic acid, is a dicarboxylic amino acid, does not show the beneficial effect of the magnesium aspartate. A comparison between the complex constants,

wherein Z is the acid anion, shows that K of the magnesium aspartate is 269 and that of magnesium glutamate only 79. However, the complex constant defines only one of a number of useful properties and is by no means alone controlling. This is best seen by a comparison with the magnesium salt of ethylene-diamine tetraacetic acid (Mg=EDTA) which has a complex constant of 5 but has no elfect in cosmetic creams. The probable reason is that the magnesium is replaced at once by other metals, particularly calcium, and is not conveyed into the cells.

The above theoretical considerations are given only as a tentative explanation and are in no way to be construed as limiting the scope of our invention.

'The favorable effects shown by cream bases containing magnesium aspartate on the skin may be reproduced in vitro by tissue cultures.

The classic model for epithelial tissue is the monkey kidney cell monolayer in cultivation flasks. The respira- 3,274,063 Patented Sept. 20, 1966 ice tion rate of both tissues is Q =8 to 10, designating the consumption of mm. of oxygen per mg. of tissue per hour.

For the tests, sterile rhesus kidney cortex tissue treated by Rapaport-trypsination, or hela cells, were suspended 1:400 in a culture medium. A's culture medium, a lactalbumin hydrolysate 0.5% in Hanks salt solution, 10% calf serum added was used.

The test flasks were filled with 90 ml. of the cell containing medium; after 7 days, the culture was treated with 0.2% trypsin solution and then centrifuged. The obtained cell quantity was measure-d in milliliters. The following table gives the results:

The growth tests show that additions of as low as 0.025% of magnesium aspartate increase the cell growth by about percent. An additional advantage of mag* nesium aspartate is its low cost and lack of any irritating effects, even when used in comparatively large proportions.

As cosmetic base, we may use any of the conventional cream bases in form of their oil-in-water or water-in-oil emulsions as they are described, for instance, in Ralph G. Harry Cosmetics, Chemical Publ. Co., New York, 1956, particularly pages 122-123, and in Kirk-Othmer, Encyclopedia of Chemical Technology, vol. 4, pp. 532 et seq.

Among the preferred bases are beeswax; water-soluble fats containing a high proportion of synthetic partial glycerides of saturated fatty hydroxyl groups containing acids having 12 to 18 C atoms, preferably in mixture with 50% of triglycerides; the bases disclosed in German Patent No. 1,090,824; the products of US. Patent No. 2,684,970, mixed with glycerol or cetyl alcohol as emollients.

The magnesium aspartate is soluble in most cream bases and may be directly incorporated therein. We prefer to prepare a concentrated solution of the magnesium aspartate and admix the solution to the cream base.

The following example serves to illustrate the invention, without, however, limiting the same hereto.

Example 1 .-C0ld cream This cream is particularly useful for restoring the smooth texture of skin which has been affected by an excessive use of mascara.

The magnesium aspartate may also be used in the form of jellies, whereby any conventional gel such as gelatin, agar-agar, alginates, carrageen, pectin, methyl cellulose may be used.

3 Example 2.Skin lotion Parts Magnesium aspartate 1 Peanut oil, ad 100 Insteadof the peanut oil, we may use other vegetable oils such as olive oil, arachis oil, castor oil, animal oils .such as neats-foot oil, spermaceti; or also mineral oils such as paraffin oil.

We claim:

1. A cosmetic preparation containing a cosmetic fatty cream base and incorporated therein about 0.05 to 10 percent by weight of magnesium aspartate, said magnesium aspartate enhancing the skin-softening effect of said cosmetic fatty base.

2. A cosmetic cream comprising an emulsion of oil in water, and from about 0.05% to 10% by weight of magnesium aspartate, said magnesium aspartate enhancing the skin-softening efiect of the cosmetic cream.

3. A cosmetic preparation comprising an oil and about 0.05 to 10 percent by weight of magnesium aspartate dis- References Cited by the Examiner UNITED STATES PATENTS 3,009,859 11/1961 Laborit et a1. 167-68 3,016,334 1/1962 Lewis 16758 3,061,512 10/1962 Anderson et al 1679l S. ROSEN, Primary Examiner.



Assistant Examiners.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3009859 *Jul 22, 1958Nov 21, 1961Andre TrzehskiPotassium aspartate and magnesium aspartate fatigue-recovery promoting process and compositions
US3016334 *Nov 24, 1958Jan 9, 1962Thomas J LewisSkin cream containing low gel strength, low viscosity gelatin
US3061512 *Jun 25, 1959Oct 30, 1962Borden CoDermatological preparation
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3932622 *Jan 11, 1974Jan 13, 1976General Foods CorporationSkin moisturizer
US6576264Oct 17, 1996Jun 10, 2003Skyepharma Canada Inc.Insoluble drug delivery
US6634576Aug 29, 2001Oct 21, 2003Rtp Pharma Inc.Milled particles
US6682761Apr 20, 2001Jan 27, 2004Rtp Pharma, Inc.Water-insoluble drug particle process
US6974593Jun 9, 2003Dec 13, 2005Jagotec AgInsoluble drug delivery
US7041705Mar 26, 2001May 9, 2006Jagotec AgInjectable aqueous dispersions of propofol
US7097849Aug 18, 1999Aug 29, 2006Jagotec AgInjectable aqueous dispersions of propofol
US7255877Mar 31, 1999Aug 14, 2007Jagotec AgFenofibrate microparticles
US7678380 *Sep 17, 2002Mar 16, 2010Lvmh RechercheCosmetic treatment method for fighting against skin ageing effects
US7939105Nov 19, 1999May 10, 2011Jagotec AgProcess for preparing a rapidly dispersing solid drug dosage form
US7939106May 23, 2003May 10, 2011Jagotec AgProcess for preparing a rapidly dispersing solid drug dosage form
US8206746Sep 30, 2002Jun 26, 2012Jagotec AgMicroparticles of water-insoluble substances
US8415329May 28, 1999Apr 9, 2013Jagotec AgThermoprotected compositions and process for terminal steam sterilization of microparticle preparations
US8586094May 2, 2003Nov 19, 2013Jagotec AgCoated tablets
US8703202Jul 24, 2006Apr 22, 2014Jagotec AgCoated tablets
US20030013693 *Apr 22, 2002Jan 16, 2003Rtp Pharma Inc.Method and composition for treatment of inflammatory conditions
US20030059484 *Sep 17, 2002Mar 27, 2003Lvmh RechercheCosmetic treatment method for fighting against skin ageing effects
US20040018229 *Jun 9, 2003Jan 29, 2004Henriksen Inge B.Insoluble drug delivery
US20040086571 *Mar 17, 2003May 6, 2004Skyepharma Canada Inc.Fibrate-statin combinations with reduced fed-fasted effects
US20090297639 *Aug 7, 2009Dec 3, 2009Lvmh RechercheCosmetic treatement method for fighting against skin ageing effects
US20100040706 *Jun 3, 2009Feb 18, 2010Lvmh RechercheMethod of anti-ageing cosmetic care by stimulation of survivin expression
U.S. Classification514/561, 514/787, 514/785
International ClassificationA61Q19/00, A61K8/67, A61Q3/00, A61K8/63, A61K8/44, A61Q7/00
Cooperative ClassificationA61K8/447, A61K8/44, A61K8/675, A61Q19/00, A61K8/63, A61Q7/00, A61Q3/00
European ClassificationA61K8/44, A61Q7/00, A61Q19/00, A61K8/63, A61K8/44K, A61K8/67F3, A61Q3/00